Copyright © Inderes 2011 - present. All rights reserved.
  • Latest
  • Markets
    • Morning Review
    • Stock Comparison
    • Financial Calendar
    • Dividends Calendar
    • Research
    • Articles
    • Transcripts
    • AGM Invitations
    • IPOs
  • inderesTV
  • Portfolio
  • Forum
  • Discovery
  • Q&A
  • About Us
    • Our Coverage
    • Team

Cereno Scientific

6.49 SEK

+3.43 %

Less than 1K followers

CRNO B

First North Stockholm

Biotechnology & Pharmaceuticals

Health Care

Overview
Financials & Estimates
Ownership
Dividend
Investor consensus
Compare
+3.43 %
+2.45 %
-7.22 %
-7.22 %
-28.30 %
+10.38 %
+267.21 %
+254.37 %
+7.88 %

Cereno Scientific is a biotechnology company. The company specializes in drug development for common and rare cardiovascular diseases. The lead drug candidate is being developed for the treatment of the rare disease pulmonary arterial hypertension, as well as for thrombotic indications. In particular, epigenetic modulation is used to develop treatments for needy patients with cardiovascular diseases. Cereno Scientific's headquarters are located in Mölndal.

Read more
Market cap
2.02B SEK
Turnover
2.37M SEK
Revenue
-
EBIT %
-
P/E
-
Dividend yield-%
-
Revenue and EBIT-%

Revenue

EBIT-% (adj.)

EPS and dividend

EPS (adj.)

Dividend %

Financial calendar
27/5
2026

Interim report Q1'26

17/6
2026

General meeting '26

26/8
2026

Interim report Q2'26

All
Webcasts
Press releases
3rd party
ShowingAll content types
Regulatory press release3/31/2026, 5:30 AM

Cereno Scientific Reports Favorable Safety and Tolerability after 12 Months of CS1 Treatment in PAH from the Expanded Access Program

Cereno Scientific
Regulatory press release3/31/2026, 5:30 AM

Cereno Scientific rapporterar gynnsam säkerhets- och tolerabilitetsprofil efter 12 månaders behandling med CS1 för PAH från Expanded Access Program

Cereno Scientific
Press release3/27/2026, 10:09 AM

Cereno Scientific: Stifel Initiates Coverage with Buy Rating and Price Target of SEK 20

Cereno Scientific

Join Inderes community

Don't miss out - create an account and get all the possible benefits

Inderes account
Followings and notifications on followed companies
Analyst comments and recommendations
Stock comparison tool & other popular tools
Create account
Press release3/27/2026, 10:09 AM

Cereno Scientific: Stifel inleder bevakning med köprekommendation och riktkurs om 20 SEK

Cereno Scientific
Third party research3/24/2026, 12:28 PM

Cereno Scientific: Inflection points coming into view - Edison

Cereno Scientific’s FY25 results mark a strategically productive period, with multiple value inflection points coming into focus in FY26. With the Phase IIb start for lead asset CS1 expected in Q226, we anticipate a step-up in clinical activity and partnering...

Cereno Scientific
Press release3/17/2026, 11:20 AM

Cereno Scientific erhåller godkännande att initiera FDA-förankrad Fas I-studie av CS014 för att stödja Fas II-utveckling i PH-ILD

Cereno Scientific
Press release3/17/2026, 11:20 AM

Cereno Scientific Receives Approval to Initiate FDA-aligned Phase I Pharmacokinetic Study of CS014 Supporting Phase II Development in PH-ILD

Cereno Scientific
Press release3/13/2026, 8:22 AM

Investor Studios: Cereno Scientifics VD intervjuas live i Market Update 11.00

Cereno Scientific
Press release3/12/2026, 6:45 AM

Cereno Scientific to Participate at BIO-Europe Spring and LSX World Congress Europe 2026 on March 23-26 in Lisbon

Cereno Scientific
Press release3/12/2026, 6:45 AM

Cereno Scientific deltar vid BIO-Europe Spring och LSX World Congress Europe 2026 den 23-26 mars i Lissabon

Cereno Scientific
Regulatory press release2/27/2026, 6:45 AM

Cereno Scientific Publishes Year-end Report for 2025 (January 1 - December 31, 2025)

Cereno Scientific
Regulatory press release2/27/2026, 6:45 AM

Cereno Scientific publicerar bokslutskommuniké för 2025 (1 januari-31 december 2025)

Cereno Scientific
Third party research2/20/2026, 10:31 AM

Cereno Scientific: CMD reaffirms shifting focus to clinical delivery - Edison

Cereno Scientific’s recent capital markets day (CMD) centered on CS1’s progression from early clinical validation into Phase IIb development, a key inflection for the investment thesis. Supported by key opinion leader (KOL) and patient perspectives, ...

Cereno Scientific
Press release2/5/2026, 11:45 AM

Investor Studios: Cereno Scientifics kapitalmarknadsdag sänds live klockan 13.00

Cereno Scientific
Press release2/4/2026, 9:00 AM

Cereno Scientific broadens development focus for CS014 to pulmonary hypertension associated with interstitial lung disease

Cereno Scientific
Press release2/4/2026, 9:00 AM

Cereno Scientific breddar utvecklingsfokus för CS014 till pulmonell hypertension associerad med interstitiell lungsjukdom

Cereno Scientific
Press release2/3/2026, 6:45 AM

Cereno Scientific Provides Update on Expanded Access Program for CS1 - initial learnings expected in Q1 2026

Cereno Scientific
Press release2/3/2026, 6:45 AM

Cereno Scientific lämnar uppdatering om Expanded Access Program för CS1 - initiala insikter förväntas under Q1 2026

Cereno Scientific
Press release2/2/2026, 1:00 PM

Cereno Scientific Announces Program and Speakers for the Capital Markets Day on February 5, 2026

Cereno Scientific
Press release2/2/2026, 1:00 PM

Cereno Scientific presenterar program och talare för kapitalmarknadsdagen den 5 februari

Cereno Scientific
Find us on social media
  • Inderes Forum
  • Youtube
  • Instagram
  • Facebook
  • X (Twitter)
Get in touch
  • info@inderes.se
  • +46 8 411 43 80
  • Vattugatan 17, 5tr
    111 52 Stockholm
Inderes
  • About us
  • Our team
  • Careers
  • Inderes as an investment
  • Services for listed companies
Our platform
  • FAQ
  • Terms of service
  • Privacy policy
  • Disclaimer
Inderes’ Disclaimer can be found here. Detailed information about each share actively monitored by Inderes is available on the company-specific pages on Inderes’ website. © Inderes Oyj. All rights reserved.